Biopsy evidenced the direct delivery of miR-34a to tumor cell cytoplasm by MRX34 treatment, whereas miR-34a target oncogenes were significantly suppressed in peripheral leukocytes in MRX34 dose-dependent manner (compared to pre-dose level, the combined mRNA expressions of B-cell lymphoma 2 (BCL2), DnaJ homolog subfamily B member 1 (DNAJB1), Catenin Beta 1 (CTNNB1), Forkhead box protein P1 (FOXP1) and Histone deacetylase 1 (HDAC1), MRX34 dose 50 (n = 4), p = 0.0005, 70 (n = 16), p = 0.0311, 93 (n = 16), p = 0.0299, 110 mg·m− 2 (n = 9), not significant)). This evidence concerns the gene DNAJB1 and neoplasm.